<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00875498</url>
  </required_header>
  <id_info>
    <org_study_id>2008-A00558-47</org_study_id>
    <nct_id>NCT00875498</nct_id>
  </id_info>
  <brief_title>Intermittent Theta Burst Stimulation (iTBS) for the Treatment of Negative Symptoms in Schizophrenia</brief_title>
  <official_title>Intermittent Theta Burst Stimulation (iTBS) for the Treatment of Negative Symptoms in Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hôpital le Vinatier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hôpital le Vinatier</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the iTBS is an effective treatment of the
      negative symptoms of schizophrenia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will evaluate whether the intermittent Theta Burst Stimulation (iTBS), a new high
      frequency TMS protocol is efficient in the treatment of the Negative Symptoms of
      schizophrenia.

      Neuroimaging studies demonstrate that hypoactivity in the left dorsolateral prefrontal cortex
      (LDLPFC) was associated with negative symptoms.

      The investigators hypothesize that iTBS applied to LDLPFC will improve negative symptoms and
      will improve activity of the LDLPFC measured with Magnetic Resonance Spectroscopy (MRS).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Scale for the Assessment of Negative Symptoms (SANS)</measure>
    <time_frame>before, after 2 weeks of treatment, and 3 times follow-up (1, 3 and 6 months)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neurochemical impact of treatment measured by 1H-MRS, DTI and resting MRI</measure>
    <time_frame>3 times, before treatment, immediatly after treatment and a last evaluation 3 months after</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>active iTBS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>iTBS active intensity = 80%MT during 6 minutes. 20 sessions, 2 per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sham iTBS</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>iTBS placebo (placebo coil)with same parameters than active</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>active iTBS</intervention_name>
    <description>Intermittent Theta Burst Stimulation (iTBS) over Left dorsolateral prefrontal cortex.
80% MT, 20 sessions of 6 minutes, 2 per day</description>
    <arm_group_label>active iTBS</arm_group_label>
    <other_name>TMS</other_name>
    <other_name>rTMS</other_name>
    <other_name>TBS</other_name>
    <other_name>iTBS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>sham iTBS</intervention_name>
    <description>iTBS placebo (placebo coil)</description>
    <arm_group_label>sham iTBS</arm_group_label>
    <other_name>placebo TMS</other_name>
    <other_name>placebo rTMS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Schizophrenia according to DSM-IV

          -  Negative symptoms for at least 6 weeks

          -  Medication resistance according to Kane et al., 1988

          -  Age between 18 and 50 years old

          -  Informed consent

        Exclusion Criteria:

          -  Contraindication to TMS

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emmanuel Poulet, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital Le Vinatier</affiliation>
  </overall_official>
  <overall_official>
    <last_name>JEROME BRUNELIN, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Hopital le Vinatier</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hopital Le vinatier</name>
      <address>
        <city>Bron</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 2, 2009</study_first_submitted>
  <study_first_submitted_qc>April 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2009</study_first_posted>
  <last_update_submitted>January 26, 2016</last_update_submitted>
  <last_update_submitted_qc>January 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hôpital le Vinatier</investigator_affiliation>
    <investigator_full_name>Dr. E. Poulet</investigator_full_name>
    <investigator_title>PUPH</investigator_title>
  </responsible_party>
  <keyword>iTBS</keyword>
  <keyword>Negative Symptoms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

